UNITHER acquired by ARDIAN
Context
Ardian, an independent private investment firm, has entered into exclusive negotiations to acquire a majority stake in Unither Pharmaceuticals, a global leader in the Contract Development and Manufacturing Organization (CDMO) sector. Ardian submitted a firm offer to Equistone, which leads a consortium of sellers including historical shareholders Parquest Capital and CM-CIC Investissement.
UNITHER, which reported an EBITDA margin of in 2016, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Global leader in sterile unit-dose manufacturing using Blow-Fill-Seal (BFS) technology. The group provides contract development and manufacturing services for pharmaceutical companies, specializing in ophthalmology, respiratory diseases, and saline solutions.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (EUR)
Other operations with UNITHER
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 10/2022 | IK PARTNERS | UNITHER | FRANCE | CDMO |
REFERENCES
Valuation range: EV 500M - 1.5b EUR
Revenue range: 250M - 500M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of UNITHER by ARDIAN are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Acquirer: ardian